ClinicalTrials.gg

Program

surlorian

Also written as “Surlorian”, “S48168 (ARM210)” and “S48168”.

Its studies are mostly in Muscular Diseases · Tachycardia, Ventricular, led by 2 companies.

Furthest: phase 2, since Oct 22, 20213 company-led studies, 1 open or runningNext primary completion: Aug 27, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Armgo Pharma20 open or runningphase 2since Oct 22, 2021Oct 24, 2019none ahead
RyCarma Therapeutics11 open or runningphase 2since Apr 7, 2026Apr 7, 2026Aug 27, 2027phase 2 · NCT07560020

Also a collaborator on its studies: celerion.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 24, 2019First study: phase 1 study in Muscular DiseasesNew to Armgo PharmaArmgo Pharma · NCT04141670 · 7 enrolled · United States
  2. Oct 22, 2021Phase 2 study in Catecholaminergic Polymorphic Ventricular Tachycardia Type 1Armgo Pharma · NCT05122975 · 8 enrolled · United States, Netherlands
  3. Apr 7, 2026RyCarma Therapeutics's first study: phase 2 study in Autosomal Dominant RYR1-Related MyopathyNew to RyCarma TherapeuticsRyCarma Therapeutics · NCT07560020 · 28 planned · France, Germany, Netherlands and more

Ahead

  1. Aug 27, 2027Primary completion: phase 2 study in Autosomal Dominant RYR1-Related MyopathyRyCarma Therapeutics · NCT07560020

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07560020Autosomal Dominant RYR1-Related Myopathy · France, Germany, Netherlands and more2RecruitingRyCarma TherapeuticsAug 27, 202728
NCT05122975Catecholaminergic Polymorphic Ventricular Tachycardia Type 1 · United States, Netherlands2TerminatedArmgo PharmaApr 1, 20248
NCT04141670Muscular Diseases · United States1CompletedArmgo PharmaDec 30, 20227

How it is read

Names in the registry

  • “Surlorian”, 1 entry
  • “S48168 (ARM210)”, 1 entry
  • “S48168”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
surlorian (Armgo Pharma): development program | ClinicalTrials.gg